Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease
Immunity, 2022
Vijayakumar B., Boustani K., Ogger P., Papadaki A., Tonkin J., Orton C., Ghai P., Suveizdyte K., Hewitt R., Desai S., Devaraj A., Snelgrove R., Molyneaux P., Garner J., Peters J., Shah P., Lloyd C., Harker J.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Respiratory Diseases Infectious Diseases | Pathophysiology | Plasma BALF |  Olink Target 96 |
Abstract
Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for many months. We delineated the immune-proteomic landscape in the airway and peripheral blood of healthy controls and post-COVID-19 patients 3 to 6 months after hospital discharge. Post-COVID-19 patients showed abnormal airway (but not plasma) proteomes, with elevated concentration of proteins associated with apoptosis, tissue repair and epithelial injury versus healthy individuals. Increased numbers of cytotoxic lymphocytes were observed in individuals with greater airway dysfunction, while increased B cell numbers and altered monocyte subsets were associated with more widespread lung abnormalities. 1 year follow-up of some post-COVID-19 patients indicated that these abnormalities resolved over time. In summary, COVID-19 causes a prolonged change to the airway immune landscape in those with persistent lung disease, with evidence of cell death and tissue repair linked to ongoing activation of cytotoxic T cells.